Overview

Topical Treatment for TMJ Arthralgia

Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are: - How does pain reduction compare? - How does improvement in jaw function limitation compare? - How do side effects compare? Participants will - On day 1 be examined and report their pain level and jaw function limitation - On days 1-21, apply their cream four times a day - On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects. Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.
Phase:
Phase 3
Details
Lead Sponsor:
University of the Pacific
Treatments:
Diclofenac
Hydrocortisone